Sarah Cannon Research Institute SCRI — Nashville, Tennessee

Sarah Cannon Research Institute SCRI is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Health Trust Score: 77/100 (FAIR). This profile has not yet been claimed by the site owner.

Sarah Cannon Research Institute SCRI has participated in 25 clinical trials with 7 currently active.

Therapeutic areas: Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma.

Sponsors: Eli Lilly and Company, Loxo Oncology, Inc., Takeda.

Sponsor Feasibility Report

Trust Score: 77/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sarah Cannon Research Institute SCRI?

Sarah Cannon Research Institute SCRI has a Crixeo Trust Score of 77/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sarah Cannon Research Institute SCRI conducted?

Sarah Cannon Research Institute SCRI has 25 clinical trials on record, with 7 currently active. Their work covers Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma.

Is Sarah Cannon Research Institute SCRI accredited by Crixeo Health?

Yes — Sarah Cannon Research Institute SCRI holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Sarah Cannon Research Institute SCRI?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.